Treatment of coenzyme Q10 for 24 weeks improves lipid and glycemic profile in dyslipidemic individuals
P Zhang, C Yang, H Guo, J Wang, S Lin, H Li… - Journal of clinical …, 2018 - Elsevier
Background The use of coenzyme Q10 (CoQ10) as an adjuvant treatment with routine
clinical therapy against metabolic diseases has shown benefit. However, the effect of CoQ10
as a primary preventive agent against cardiovascular diseases (CVDs) has not been well
studied. Objective The objective of this study was to investigate the effect of CoQ10 on CVD
risk factors in dyslipidemic patients. Methods In this randomized, double-blinded, placebo-
controlled trial, 101 dyslipidemic subjects without taking any hypoglycemic or hypolipidemic …
clinical therapy against metabolic diseases has shown benefit. However, the effect of CoQ10
as a primary preventive agent against cardiovascular diseases (CVDs) has not been well
studied. Objective The objective of this study was to investigate the effect of CoQ10 on CVD
risk factors in dyslipidemic patients. Methods In this randomized, double-blinded, placebo-
controlled trial, 101 dyslipidemic subjects without taking any hypoglycemic or hypolipidemic …
